Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty

Summary

The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method for platelet density measurements (MPC, Mean Platelet Component Concentration), on the automated ADVIA 120 Hematology System and by the classic measurement of P-selectin (CD62P) expression, on a fluorescence flow cytometer. Patients received a loading dose of clopidogrel (300 mg; n = 29) or a bolus of abciximab (0.25 mg/kg; n = 15). Blood samples were collected before (baseline) and at different times after PTCA and antiplatelet drugs administration. Our data showed a close inverse correlation between the change in MPC and the CD62P fluorescence surface marker expression (r = 0.776, P<0.0001). Individual platelet activation determinations in patients receiving either clopidogrel or abciximab showed a variation in platelet activation as assayed by MPC and CD62P expression. Patients were characterized as having either high platelet activity upon admission and positive response to treatment or no detectable platelet activation before or after treatment. This study demonstrates the heterogeneity of platelet activation states in ACS patients undergoing coronary angioplasty. The present work also illustrates the potential use of the MPC parameter, generated on an automated hematology system, to define high risk patients and to monitor the variability of platelet response to anti-platelet therapies.

Keywords

Platelets activation - anti-platelet drugs - ADVIA 120 - CD62P

• References

• 1 Fitzgerald DJ, Roy L, Catella F. et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
• 2 Hamm CW, Lorenz RL. et al. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987; 10: 998-1006.
• 3 Schultheiss HP, Tschoepe D, Esser J. et al. Large platelets continue to circulate in an activated state after myocardial infraction. Eur J Clin Invest 1994; 24: 243-7.
• 4 Tschoepe D, Schultheiss HP, Kolarov P. et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
• 5 Lewis HD, Davis JW, Archibald DG. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
• 6 Jarvis B, Simpson K. Clopidogrel: A review of its use in the prevention of atherothrombosis. Drugs 2000; 60: 347-377.
• 7 Moshfegh K, Redondo M, Friedgard J. et al. Anti-platelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36: 699-705.
• 8 Rupprecht HJ, Darius H, Borkowski U. et al. Comparison of anti-platelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998; 97: 1046-52.
• 9 PRISM Study Group. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
• 10 PRISM-PLUS Study Group. Inhibition of the platelet glycoprotein IIb/IIIa receptor with Tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-997.
• 11 The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
• 12 The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997; 349: 1429-35.
• 13 Mascelli MA, Lance ET, Damaraju L. et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockage. Circulation 1998; 97: 1680-8.
• 14 Aguirre FV, Topol EJ, Ferguson JJ. et al. Bleeding complications with the chimeric antibody to platelet glycoprotein 11b/111a integrin in patients undergoing percutaneous coronary intervention. Circulation 1995; 91: 2882-90.
• 15 Bihour C, Durrieu-Jais C, Macchi L. et al. Expression of markers of Platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol 1999; 16: 212-9.
• 16 Kleiman NS, Raizner AE, Jordan R. et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab : implications for inhibition of the internal pool of GP11b-111a receptors. J Am Coll Cardiol 1995; 26: 1665-71.
• 17 Steinhubl SR, Talley JD, Braden GA. et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AUAssessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8.
• 18 Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: Methods and clinical applications. Blood Coagul Fibrinolysis 1994; 05: 121-31.
• 19 Michelson AD, Barnard MR, Krueger LA. et al. Evaluation of platelet function by flow cytometry. Methods 2000; 21: 259-70.
• 20 Macey MG, Carty E, Webb L. et al. Use of mean platelet component to measure platelet activation on the ADVIA 120 haematology system. Cytometry 1999; 38: 250-5.
• 21 Chapman ES, Sorette M, Hetherington E. et al. A rapid, automated flow cytometric method to measure activated degranulated platelets by density determination. Thromb Haemost 2003; 89: 1004-15.
• 22 Ahnadi CE, Chapman S, Lépine M. et al. Assessment of platelet activation in several different anticoagulants by the ADVIA 120 Hematology System, fluorescence flow cytometry, and electron microscopy. Thromb Haemost 2003; 90: 940-8.
• 23 Brummitt DR, Barker HF. The determination of a reference range for new platelet parameters produced by the Bayer ADVIA 120 full blood count analyser. Clin Lab Haem 2000; 22: 103-7.
• 24 Schomig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
• 25 Moshfegh K, Redondo M, Julmy F. et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36: 699-705.
• 26 Serebruany VL, Cummings CC, Malinin AI. et al. Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. Am Heart J 2001; 142: 611-6.
• 27 Nurden AT. Polymorphism of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost 1995; 74: 345-51.
• 28 Serebruany VL, Gurbel PA, Shustov AR. et al. Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. Am Heart J 1998; 136: 398-405.
• 29 Gurbel PA, McKenzie ME, Serebruany VL. Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens?. Thromb Res 2000; 99: 105-7.